Related Experiment Videos
Progelatinase A activation during tumor cell invasion
1Extracellular Matrix Pathology Section, Bethesda, Md 20892, USA.
Invasion & Metastasis
|January 1, 1994
Summary
Malignancy arises from defects in regulating cellular invasion. The activation of progelatinase A (MMP-2), a key enzyme in invasion, is crucial for malignant potential. Tissue inhibitor of metalloproteinases-2 plays a role in this activation process.
Area of Science:
- Molecular Biology
- Cancer Research
- Cellular Biology
Background:
- Tumor cell invasion shares mechanisms with normal cell invasion.
- Malignancy can be viewed as a regulatory defect in the cellular invasion program.
- Gelatinase A (MMP-2) is implicated in the invasive phenotype of cancer cells.
Purpose of the Study:
- To review recent findings on the cellular mechanisms of progelatinase A activation.
- To explore the role of tissue inhibitor of metalloproteinases-2 (TIMP-2) in progelatinase A activation.
Main Methods:
- Review of recent scientific literature on matrix metalloproteinases and cancer invasion.
- Analysis of cellular pathways involved in progelatinase A activation.
- Examination of the regulatory function of TIMP-2.
Main Results:
- Progelatinase A activation is a critical step in acquiring malignant potential.
- The cellular mechanisms governing invasion are conserved between normal and malignant cells.
- TIMP-2 is identified as a key regulator in the activation of progelatinase A.
Conclusions:
- Understanding progelatinase A activation is vital for targeting cancer invasion.
- Defects in the regulation of cellular invasion define malignancy.
- TIMP-2's role in MMP-2 activation offers potential therapeutic insights.